Streetbeat News

Analyst Ratings

RNA

Avidity Biosciences (NASDAQ:RNA) has received diverse analyst ratings over the last three months, with a significant upward trend in its 12-month price target to $37.29, indicating a 62.13% increase from the previous average of $23.00. Analysts from firms like B of A Securities, Needham, Cantor Fitzgerald, and Chardan Capital have adjusted their ratings and price targets, reflecting a bullish outlook on the company. Despite this optimism, Avidity Biosciences faces challenges in revenue growth and efficiency metrics, with a notable revenue decline of -20.8% and concerns in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 12:00 pm

ENOV

Recent analyst ratings for Enovis (NYSE:ENOV) show a mix of bullish sentiments with an updated average 12-month price target of $78.67, reflecting a 7.77% increase from the previous target. The company's financial performance indicates strong revenue growth, profitability, and efficient asset and debt management, positioning it favorably in the medical technology sector.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 12:00 pm

CGNX

Over the last three months, Cognex (NASDAQ:CGNX) has been evaluated by 5 analysts, showing a mix of bullish and indifferent sentiments. The average 12-month price target for CGNX has been raised to $47.2, reflecting an 11.72% increase from the previous target of $42.25. Analysts from firms including Needham, Baird, Citigroup, UBS, and Truist Securities have adjusted their ratings and price targets, indicating a positive outlook on the stock. Despite facing revenue challenges with a -17.86% decline over 3 months, Cognex's financial strength is evident in its net margin, ROE, ROA, and low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 12:00 pm

CMI

Cummins (NYSE:CMI) has been the subject of diverse analyst opinions ranging from bullish to bearish over the past quarter, with a total of 7 analysts offering their views. The recent evaluations show a shift towards a more neutral stance in the last 30 days compared to previous months. The average 12-month price target for Cummins has been raised to $289.86, indicating an 11.27% increase from the previous target of $260.50. Analysts from firms including Baird, Goldman Sachs, JP Morgan, UBS, Truist Securities, Evercore ISI Group, and Citigroup have updated their ratings and price targets, reflecting various adjustments based on market conditions and company performance. Cummins, a leading manufacturer of diesel engines and powertrain components, has shown strong financial performance with a notable revenue growth rate and above-average market capitalization, despite challenges in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 12:00 pm

PARA

Seaport Global analyst David Joyce downgrades Paramount Global (NASDAQ:PARA) from Buy to Neutral.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 12:00 pm

TXRH

Wedbush analyst Nick Setyan maintains an Outperform rating on Texas Roadhouse (TXRH) and raises the price target from $170 to $180.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 11:57 am

ACLS

Craig-Hallum analyst Christian Schwab upgrades Axcelis Technologies (ACLS) from Hold to Buy, maintaining a $130 price target.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 11:56 am

BKNG

B of A Securities analyst Justin Post maintains a Neutral rating on Booking Holdings (NASDAQ:BKNG) and raises the price target from $3900 to $3950.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 11:55 am

BJRI

Wedbush analyst Nick Setyan reiterates an Outperform rating on BJ's Restaurants (NASDAQ:BJRI) and maintains a $40 price target.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 11:54 am

WEN

Wedbush analyst Nick Setyan maintains a Neutral rating on Wendy's (NASDAQ:WEN) and raises the price target from $20 to $21.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 11:53 am